Story preview
Continue reading on the publisher site for the full article.
Read on publisher →Stock Titan
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Context from Wikipedia on the organisations, people and places in this story.
American pharmaceutical company
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
More on Wikipedia ↗Outlets covering it
7
in the last 3 days
First reported
20 hr. ago
5 outlets since
Countries
6 other outlets reported this story in the last 3 days.
Direct holdings totaled 161,096 shares after Andrew D. Dickinson's October 15, 2026 sale under a trading plan adopted on August 29, 2024.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the firm
Andrew Dickinson, Chief Financial Officer of Gilead Sciences Inc (GILD), sold 3,000 shares of the company on 2026-10-15, according to a recent SEC Filing. F